In 2012, the Hh pathway inhibitor vismodegib (GDC-0449), an oral small molecule inhibitor of SMO was the first drug to gain U.S. Food and Drug Administration approval for treatment of advanced BCC, metastasized BCC, relapsed BCC after surgery, or BCC that cannot be treated with surgery or radiation [13,14]. Here, SMO is linked to skin basal cell carcinoma.